A Cancer Charity Took Alcohol Industry Money for Years. Then It Admitted There's No Safe Amount.

For years, the American Cancer Society took gala donations from the alcohol industry. During those same years, its public guidance told Americans that moderate drinking was safe. Len Lichtenfeld, the charity’s former deputy chief medical officer, watched the money come in and the guidance stay put. He didn’t say anything publicly at the time. He’s saying it now. “It stayed with me,” he told STAT News, “because I knew it was a conflicted situation.”

That sentence is the whole story, and it took the American Cancer Society until 2020 to catch up to what its own scientists already knew: there is no safe level of alcohol consumption when it comes to cancer risk.

The people who told you a drink a day was fine were being paid by the people who sell the drink.

That’s not a conspiracy theory. It’s the finding of a seven-part investigative series by STAT News, and it lands on a specific institution, with a specific former official, saying on the record that he knew something was off and stayed quiet anyway. William Dahut, ACS’s current chief scientific officer, defends the 2020 reversal as overdue but correct: “It was the right thing to do in 2020. The whole committee endorsed strongly where we stand now.” Nobody at ACS is claiming the earlier guidance was based on better evidence. They’re claiming the newer evidence changed the picture — which raises the obvious question of why gala money from the industry being studied was ever in the room while that picture was being drawn.

The Charity That Took the Money and Kept Its Story Straight — Until It Couldn’t

The mechanism here isn’t complicated, which is what makes it so hard to defend. A cancer charity relies on donations to fund research and operations. The alcohol industry, like the tobacco industry before it, has a long history of funding health institutions, medical conferences, and “responsible drinking” campaigns — not out of civic generosity, but because a friendly relationship with the messenger shapes the message. ACS took that money for years while telling the public that moderate drinking carried no meaningful cancer risk. That guidance wasn’t a fringe opinion. It shaped how doctors talked to patients, how nutrition labels got written, how a glass of wine at dinner got coded as harmless self-care.

Then, in 2020, ACS reversed itself. The new guidance says plainly that there is no safe level of alcohol consumption with respect to cancer — not a low-risk threshold, not a “moderate” carve-out, a zero. Dahut frames the shift as science evolving. Lichtenfeld’s quote suggests something closer to institutional discomfort finally outweighing institutional inertia. Both things can be true. What’s also true is that the interval between “the industry is funding us” and “we changed our guidance” wasn’t measured in months. It was measured in years — years during which people who trusted the American Cancer Society’s name built their daily habits around advice that the institution itself would later disown.

This is the part that should sit with you if you’ve ever heard “a glass of red wine is basically medicine” and filed it away as settled science. It wasn’t settled. It was funded.

This Is the Tobacco Playbook, Run With a Better PR Team

STAT News draws this comparison explicitly, and it’s not a stretch — it’s a documented historical rhyme. Starting in the 1950s, as independent research began linking cigarettes to lung cancer, the tobacco industry didn’t dispute the science quietly behind closed doors. It built an entire infrastructure to manufacture public doubt: a research council that funded friendly studies, a rotating cast of credentialed scientists willing to say the evidence was “inconclusive,” full-page newspaper ads promising more research was needed, and decades of lobbying that delayed mandatory warning labels long after the industry’s own internal scientists had already confirmed the harm in memos that stayed sealed for decades. The strategy wasn’t to win the scientific argument. It was to keep the public argument going just long enough that regulation, litigation, and behavior change all got delayed by a generation. Internal tobacco documents later surfaced with a line that became infamous inside public health circles: doubt is our product, because it’s the best means of competing with the “body of fact” that existed in the mind of the general public. The alcohol industry didn’t invent this playbook. It inherited it, and STAT’s reporting shows the same architecture — philanthropy, gala entanglement, friendly research relationships — doing the same job of buying time.

STAT News draws this comparison explicitly, and it’s not a stretch — it’s a documented historical rhyme.

The Industry Is Chasing the Drinkers It’s Losing

Here’s the twist: the public is drinking less anyway, industry messaging notwithstanding. Gallup data cited in a commentary by researcher Katherine Keyes in the journal Addiction shows the share of Americans who drink at all fell from 62% in 2023 to 54% in 2025, and people who still drink are drinking less when they do. Keyes calls the trend “emerging but not definitive” — meaning real, but too recent to call a permanent shift yet. Globally, the World Health Organization’s SAFER report estimates alcohol still causes about 2.6 million deaths a year, and finds that only 7% of UN country-level health cooperation plans between 2020 and 2023 even prioritized alcohol as a policy issue, despite that death toll. The WHO’s SAFER framework, for the record, is a five-part policy checklist — things like raising alcohol taxes, restricting marketing, tightening drink-driving laws, and expanding screening — designed to give governments a concrete menu instead of vague awareness campaigns. Uganda just became the first country to adopt it nationally, and Nepal’s Supreme Court upheld a nationwide alcohol-ad ban this year.

Meanwhile, the industry’s response to shrinking demand isn’t better transparency — it’s a pivot toward newer drinkers. The Institute of Alcohol Studies audited 530 alcohol products in the UK this June and found that 90% carry vague “drink responsibly” self-regulation messaging, while only 1.3% display any cancer warning at all. Ready-to-drink cocktail sales are up 17% in value, packaged in soda-can branding that researchers are now calling “kidification” — bright colors, fruit flavors, and design language borrowed straight from the beverage aisle your little cousin shops in. The generation that’s drinking less overall is being offered a product line engineered to look like the ones that aren’t alcohol at all.

What Changes When You Stop Waiting for Institutions to Lead

If you’re in recovery, or cutting back, or just paying attention because someone you love isn’t — you already know the gap between “official guidance” and “what actually helped you” can be enormous. You didn’t need a 2020 memo from a cancer charity to know that drinking wasn’t neutral for you. But the ACS story matters anyway, because it explains why the information environment felt so muddled for so long: not because the science was genuinely unclear, but because some of the loudest institutional voices had a donor in the room. That’s worth being angry about, and it’s worth naming specifically — Lichtenfeld didn’t say the money changed the guidance; he said it stayed with him because he knew it was compromised. That’s a person inside an institution telling you the quiet part.

The reason to trust what you’re reading about alcohol now, more than what you read a decade ago, isn’t blind faith in institutions catching up. It’s that the newest findings are landing in public, unfiltered by gala tables — the WHO’s global death count, the UK’s labeling audit, Keyes’ drinking-rate data — and they’re consistent with each other in a way the old “moderation is fine” consensus never actually was.

Before you carry any of this as one more reason to feel hopeless about who to believe: the corrected science is out now, published and free to read, not sealed in an internal memo the way tobacco’s was for forty years. And treatment is moving, not just messaging — a new Phase 3 trial (the last, largest stage of testing before a drug can be approved for a new use) began enrolling US veterans with alcohol use disorder on July 1, testing whether weekly semaglutide can reduce drinking over 28 weeks. Real experiments, run in the open, aimed at people who need something better than a gala-funded pamphlet.

The lesson of the ACS story isn’t “trust nothing.” It’s “ask who’s in the room.” An institution can be well-intentioned, staffed by people like Lichtenfeld who privately know something’s wrong, and still take years to say so out loud — because saying so out loud costs money, relationships, and comfort that the institution had gotten used to. The alcohol industry is frazzled right now because people are drinking less and asking more questions, and frazzled industries don’t get quieter. They get better at looking generous. Watch the gala list, not just the guidance.

The alcohol industry is frazzled right now because people are drinking less and asking more questions, and frazzled industries don’t get quieter.